Please login to the form below

Not currently logged in
Email:
Password:

Henry Skinner has been appointed as the first CEO of the AMR Action Fund

The AMR Action Fund is aiming to strengthen and accelerate antibiotic development

Henry Skinner (pictured above) has been appointed the first chief executive officer of the AMR Action Fund, an initiative aiming to strengthen and accelerate antibiotic development.

Skinner joins the AMR Action Fund with extensive biomedical and investment funding experience, having spent decades in the biomedical research, venture and the pharmaceutical industries.

Most recently, he served as the senior vice president of venture at Tekla Capital Management.

Prior to that, he has served as vice president and deputy head and managing director of the Novartis Venture Fund, as well as executive director, head strategic alliances at Novartis Institutes for Biomedical Research.

Skinner also worked as the chief executive officer of the small, antibiotic-focused biotech SelectX Pharmaceuticals and president and chief executive officer at NeoGenesis Pharmaceuticals.

“I am honoured to join the AMR Action Fund and its incredibly important mission. Having worked on this issue from many angles throughout my career, I know how badly novel antibiotics are needed, and I also know how many obstacles currently prevent them from being developed and reaching patients," commented Skinner.

"I am proud and excited to lead the AMR Action Fund in its efforts to tackle the global challenge of AMR. Thank you to everyone involved in developing this critical and groundbreaking initiative, and in particular to the interim CEO of the AMR Action Fund, Martin Bott, for getting us to this point," he added.

The AMR Action Fund is an initiative created to bring two to four new antibiotics to patients by 2030 – treatments which are urgently needed to address the rapid rise of antibiotic resistance, which is a part of the broader issue of antimicrobial resistance.

It was developed by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and its member biopharmaceutical companies, in collaboration with the World Health Organization (WHO), the European Investment Bank and the Wellcome Trust

Article by
Lucy Parsons

19th February 2021

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...